Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect genuine interest and moderate engagement, exemplified by comments like 'Great to work with' and references to new preprints, indicating researchers value the methodological advances and potential for targeted therapies. The tone is analytical yet optimistic, emphasizing the study's relevance to ongoing efforts in AML research.
Most discussions acknowledge or affirm the significance of the study, especially noting the distinction between the two leukemia groups and their therapeutic implications.
Participants display high curiosity, highlighting the innovative methodologies like phosphoproteomics and the potential clinical benefits.
Comments include mentions of collaboration and ongoing projects, suggesting a moderate level of active engagement and relevance to ongoing research.
The discourse hints at recognition that these findings could influence future treatments, but the overall tone suggests a developing understanding rather than immediate paradigm shifts.
1st preprint for our Poor Risk AML project. Great to work with @pedro_cutillas and @anariomachin Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes https://t.co/BIYUnuEmwn
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes https://t.co/e1CpPp1wy5 #bioRxiv
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged ac... https://t.co/Ereh5S1qY4
TW : Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute...: Samples were collected by the Barts Cancer Institute tissue bank in UK ( n = 56) and the Institute for Molecular Medicine... https://t.co/l7UlKQrLlS https://t.co/tY0vUiL9jc
This study explores two distinct subgroups of KMT2A rearranged AML, MLLGA and MLLGB, showing different biological traits and drug sensitivities, emphasizing potential for targeted therapies based on phosphoproteomic…
New from #CR_UK https://t.co/LvHzAkUTok Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged ac... https://t.co/Ereh5S1qY4
TW : Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute...: Samples were collected by the Barts Cancer Institute tissue bank in UK ( n = 56) and the Institute for Molecular Medicine... https://t.co/l7UlKQrLlS https://t.co/tY0vUiL9jc
1st preprint for our Poor Risk AML project. Great to work with @pedro_cutillas and @anariomachin Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes https://t.co/BIYUnuEmwn
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes https://t.co/e1CpPp1wy5 #bioRxiv